MorphoSys AG at UBS Global Healthcare Virtual Conference Transcript
Hi, everyone. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Thank you very much for joining us at the UBS Healthcare Conference. Very happy to have MorphoSys here with us today. With us from MorphoSys is Jean-Paul Kress, CEO. We'll be doing a fireside chat format today. And with that, I'll turn it over to you, Jean-Paul. Maybe high level, you can -- for those less familiar with the story, give us some background on MorphoSys, your antibody capabilities? And kind of high-level what your key goals are over the coming years.
Thanks, Ellie. And thanks for having me. Hi, everyone. Sure. So MorphoSys has been for several years, a leader in antibody discovery, engineering and development. We have established HQs many years ago in Germany, close to Munich, and we've recently expanded in the United States to launch our first proprietary asset, tafasitamab or Monjuvi, I'm sure we'll talk about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
